FOR IMMEDIATE RELEASE: July 11, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Rising Number of Hospital Mergers and Closures in Rural America Hurting Women’s Health, Economic Well-Being Roosevelt Institute documents adverse effects of market power crisis An issue brief released today by the Roosevelt Institute finds that corporate consolidation within America’s rural hospital sector is harming both

Structural problems in the health care and hospital industries are specifically hurting women in rural America, both as patients and as workers. In a new Roosevelt issue brief, Andrea Flynn, Rakeen Mabud, and Emma Chessen explore some of the industry-wide shifts that have occurred in rural areas over the last several decades. They then describe the

In a working paper, Roosevelt Senior Economist and Policy Counsel Lenore Palladino investigates whether stock buybacks occur more frequently, independent of other factors, when corporate insiders are selling their own personal shareholdings. In her empirical analysis of the relationship between insider sales and stock buybacks, Palladino finds that a 10 percent increase in insider sales

FOR IMMEDIATE RELEASE: June 19, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org The High Cost of Shareholder Power in Big Pharma New Roosevelt brief illustrates the magnitude of Big Pharma spending on shareholders NEW YORK, NY – At a time when Americans pay record prices for medications, pharmaceutical companies generate record profits devoted largely to rewarding shareholders

Despite Big Pharma’s claim that high-cost medicines are the price society must pay for innovation, recent research provides ample evidence that overpriced medicines are not necessary for the industry to find cures or revolutionize. Rather, high-cost and low-quality medicines are the price patients pay for an industry that prioritizes profit-seeking over public health. Like all

The pharmaceutical industry isn’t working for most people in the US. Over 80 percent of Americans across the political spectrum believe that lowering drug costs should be a “top priority” for lawmakers and believe that prescription drug costs are “unreasonable.” This growing scrutiny presents an opportunity to question the ways that drug corporations run business, as

FOR IMMEDIATE RELEASE: February 21, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Kathy Mulady, k.mulady@peoplesaction.org   Creation of a Crisis: Why the Pharmaceutical Industry Chooses Profit Over People New issue brief explores how US policy choices have led to high drug prices, low health care investment, misaligned incentives, and escalating CEO pay across the pharmaceutical industry  

For nearly half of a century, America’s public corporations have been driven by a shareholder primacy approach to corporate governance, increasingly prioritizing shareholder payments over other, more productive uses of corporate resources. Over the same period, employee bargaining power has decreased and wages for nonexecutive workers have remained flat across sectors. In Ending Shareholder Primacy in Corporate Governance,

FOR IMMEDIATE RELEASE: February 14, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org   Roosevelt Senior Economist Explores Corporate Prosperity and the Decline of Employee Bargaining Power Research finds that the rise of shareholder primacy has contributed to America’s high-profit, low-wage economy   NEW YORK, NY – Today, the Roosevelt Institute, a New York-based think tank that promotes

The 2016 corruption scandal at Wells Fargo, in which executives pressured employees to meet “wildly unrealistic sales targets,” created a work environment described as “relentless pressure.” Once revealed, the massive fraud committed against millions of consumers led to congressional hearings, substantial fines by state and federal regulators, and a series of announced changes by Wells